<DOC>
	<DOC>NCT00318162</DOC>
	<brief_summary>This study will examine the effects of low-dose naltrexone (LDN) on children with autistic spectrum disorders. The investigators hope to show a positive effect on social functioning and language.</brief_summary>
	<brief_title>Trial of Low-Dose Naltrexone for Children With Pervasive Developmental Disorder (PDD)</brief_title>
	<detailed_description>Fifty children aged three to six years will be recruited for the study. They will be randomly assigned to receive either LDN or placebo for two months after which the treatment groups will be switched over. Assessments of functioning will be obtained from a video-taped play session, and by parent and teacher questionnaires at baseline, after two months and after four months.</detailed_description>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders, Pervasive</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Diagnosis of PDD</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>autism</keyword>
	<keyword>PDD</keyword>
	<keyword>LDN</keyword>
	<keyword>naltrexone</keyword>
</DOC>